Astellas

Recommended regenerative medicine reads plus COVID-19 stem cell hype

Universal-Cells

Despite the COVID-19 pandemic there are still some research things we can do including data analysis as well as reading new papers and media articles on science, including regenerative medicine. If the weather’s good and you have wi-fi (or you print articles still on paper) you can even do this out in the fresh air …

Recommended regenerative medicine reads plus COVID-19 stem cell hype Read More »

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work

VC-01-post-implant-final1-e1503703572933, viacyte

We heard this week about the encouraging news of a new CRISPR-stem cell collaboration between stem cell biotech ViaCyte and CRISPR Therapeutics. The goal of the team is to make genetically engineered pancreatic derivatives from stem cells that would have a unique immune stealthiness. If such an approach was successful, patients would not need to …

Quick Q&A with ViaCyte CEO on CRISPR-stem cell work Read More »

Stem cell news bites: Astellas trial, cystic fibrosis claim, a few cool papers

Matoba-et-al-Figure-2c-2018

Stem cell news is always burbling up, sometimes right there in front of us on the web and other times via networks of people. Astellas news. Some may remember there used to be this pioneering stem cell biotech called ACT, which then became Ocata, and finally was acquired by the big company Astellas. One of …

Stem cell news bites: Astellas trial, cystic fibrosis claim, a few cool papers Read More »

Grading my stem cell predictions for 2016: how’d I do?

stem-cell-predictions

Below are the 2016 stem cell predictions I made last year and their status now color-coded near year’s end. Green is right, orange is mixed bag, and red is flat out wrong. Overall, I did better than most past years with only having entirely blown it on four. Stay tuned later this week for my 2017 predictions, …

Grading my stem cell predictions for 2016: how’d I do? Read More »

REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises

Center-for-Responsive-Politics

The money behind a piece of legislation can provide unique insights into the back story and this is definitely true for the REGROW Act that would reduce FDA oversight of the investigational use of stem cells in patients. Senator Mark Kirk of Illinois, who is facing probable defeat next week in his reelection bid according to …

REGROW Act, Mark Kirk Lobbying & Contributions Yield Stem Cell Surprises Read More »

Stem Cell News Briefs: Anversa, Japan Regs, Ocata Suit, More

Timothy-J.-Kieffer

It’s been a busy few weeks for the stem cell field. Below are some news briefs on developments. RetractionWatch reports that Piero Anversa is leaving Harvard/Brigham and Women’s Hospital after an investigation and dismissed lawsuit he filed against the institution. All still quiet on the STAP cell front at the same institutions. There’s some more …

Stem Cell News Briefs: Anversa, Japan Regs, Ocata Suit, More Read More »

What is Astellas Pharma, the purchaser of Ocata?

Fish-eating-fish

Astellas Pharma is on track to purchase Ocata Therapeutics (formerly Advanced Cell Technology). This has stirred a lot of strong feelings amongst investors in Ocata. (Update, now almost 5 years later, the Ocata vision program is still not going full steam ahead at its new owner it seems). I’ve also been wondering what exactly is …

What is Astellas Pharma, the purchaser of Ocata? Read More »